Wockhardt: Analysis of news alert and 15-minutes built-up screen

Posted on April 4, 2017

Wockhardt was in action on Monday after the drug maker said the US health regulator agreed to abridged clinical trials for antibiotic being developed by the company. Wockhardt recorded a jump of 6.46 percent in share price on Monday.

The company is developing superdrug antibiotic WCK 5222. The drug is expected to be a life-saving therapy for serious hospital acquired infections. The aforesaid US FDA approval will help Wockhardt to speed up phase III clinical trials for the drug.

Read the rest of this entry »